Anti-inflammatory mediators as physiological and pharmacological regulators of parturition

References

• Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet371(9606), 75–84 (2008).
   PubMed Web of Science ®Google Scholar
• Sennstrom MB, Ekman G, Westergren-Thorsson G et al. Human cervical ripening, an inflammatory process mediated by cytokines. Mol. Hum. Reprod.6(4), 375–381 (2000).
   PubMed Web of Science ®Google Scholar
• Young A, Thomson AJ, Ledingham M, Jordan F, Greer IA, Norman JE. Immunolocalization of proinflammatory cytokines in myometrium, cervix, and fetal membranes during human parturition at term. Biol. Reprod.66(2), 445–449 (2002).
   PubMed Web of Science ®Google Scholar
• Osman I, Young A, Ledingham MA et al. Leukocyte density and pro-inflammatory cytokine expression in human fetal membranes, decidua, cervix and myometrium before and during labour at term. Mol. Hum. Reprod.9(1), 41–45 (2003).
   PubMed Web of Science ®Google Scholar
• Denison FC, Kelly RW, Calder AA, Riley SC. Cytokine secretion by human fetal membranes, decidua and placenta at term. Hum. Reprod.13(12), 3560–3565 (1998).
   PubMed Web of Science ®Google Scholar
• Olson DM. The role of prostaglandins in the initiation of parturition. Best Pract. Res. Clin. Obstet. Gynaecol.17(5), 717–730 (2003).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Sagawa N, Itoh H et al. Prostaglandin F(2α), cytokines and cyclic mechanical stretch augment matrix metalloproteinase-1 secretion from cultured human uterine cervical fibroblast cells. Mol. Hum. Reprod.8(7), 681–687 (2002).
   PubMed Web of Science ®Google Scholar
• Xu P, Alfaidy N, Challis JR. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human placenta and fetal membranes in relation to preterm and term labor. J. Clin. Endocrinol. Metab.87(3), 1353–1361 (2002).
   PubMed Web of Science ®Google Scholar
• Tribe RM, Moriarty P, Dalrymple A, Hassoni AA, Poston L. Interleukin-1β induces calcium transients and enhances basal and store operated calcium entry in human myometrial smooth muscle. Biol. Reprod.68(5), 1842–1849 (2003).
   PubMed Web of Science ®Google Scholar
• Barata H, Thompson M, Zielinska W et al. The role of cyclic-ADP-ribose-signaling pathway in oxytocin-induced Ca2+ transients in human myometrium cells. Endocrinology145(2), 881–889 (2004).
   PubMed Web of Science ®Google Scholar
• Pollard JK, Mitchell MD. Intrauterine infection and the effects of inflammatory mediators on prostaglandin production by myometrial cells from pregnant women. Am. J. Obstet. Gynecol.174(2), 682–686 (1996).
   PubMed Web of Science ®Google Scholar
• Bollapragada S, Youssef R, Jordan F, Greer I, Norman J, Nelson S. Term labor is associated with a core inflammatory response in human fetal membranes, myometrium, and cervix. Am. J. Obstet. Gynecol.200(1), 104 e101–e111 (2009).
   PubMed Web of Science ®Google Scholar
• Thomson AJ, Telfer JF, Young A et al. Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process. Hum. Reprod.14(1), 229–236 (1999).
   PubMed Web of Science ®Google Scholar
• Gomez-Lopez N, Estrada-Gutierrez G, Jimenez-Zamudio L, Vega-Sanchez R, Vadillo-Ortega F. Fetal membranes exhibit selective leukocyte chemotaxic activity during human labor. J. Reprod. Immunol.80(1–2), 122–131 (2009).
   PubMed Web of Science ®Google Scholar
• Osman I, Young A, Jordan F, Greer IA, Norman JE. Leukocyte density and proinflammatory mediator expression in regional human fetal membranes and decidua before and during labor at term. J. Soc. Gynecol. Investig.13(2), 97–103 (2006).
   PubMedGoogle Scholar
• Thaxton JE, Romero R, Sharma S. TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes. J. Immunol.183(2), 1144–1154 (2009).
   PubMed Web of Science ®Google Scholar
• Murphy SP, Hanna NN, Fast LD et al. Evidence for participation of uterine natural killer cells in the mechanisms responsible for spontaneous preterm labor and delivery. Am. J. Obstet. Gynecol.200(3), 308 e301–e309 (2009).
   PubMed Web of Science ®Google Scholar
• Yuan M, Jordan F, Mcinnes IB, Harnett MM, Norman JE. Leukocytes are primed in peripheral blood for activation during term and preterm labour. Mol. Hum. Reprod.15(11), 713–724 (2009).
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev.18(18), 2195–2224 (2004).
   PubMed Web of Science ®Google Scholar
• Lindstrom TM, Bennett PR. The role of nuclear factor κ B in human labour. Reproduction130(5), 569–581 (2005).
   PubMed Web of Science ®Google Scholar
• Lappas M, Rice GE. The role and regulation of the nuclear factor κ B signalling pathway in human labour. Placenta28(5–6), 543–556 (2007).
   PubMedGoogle Scholar
• Elliott CL, Allport VC, Loudon JA, Wu GD, Bennett PR. Nuclear factor-κ B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol. Hum. Reprod.7(8), 787–790 (2001).
   PubMed Web of Science ®Google Scholar
• Lappas M, Permezel M, Rice GE. N-acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-κB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J. Clin. Endocrinol. Metab.88(4), 1723–1729 (2003).
   PubMed Web of Science ®Google Scholar
• Lindstrom TM, Bennett PR. 15-deoxy-{δ}12,14-prostaglandin j2 inhibits interleukin-1{β}-induced nuclear factor-{κ}b in human amnion and myometrial cells: mechanisms and implications. J. Clin. Endocrinol. Metab.90(6), 3534–3543 (2005).
   PubMedGoogle Scholar
• Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene25(51), 6758–6780 (2006).
   PubMed Web of Science ®Google Scholar
• Allport VC, Pieber D, Slater DM, Newton R, White JO, Bennett PR. Human labour is associated with nuclear factor-κB activity which mediates cyclo-oxygenase-2 expression and is involved with the ‘functional progesterone withdrawal’. Mol. Hum. Reprod.7(6), 581–586 (2001).
   PubMed Web of Science ®Google Scholar
• Lee Y, Allport V, Sykes A, Lindstrom T, Slater D, Bennett P. The effects of labour and of interleukin 1 β upon the expression of nuclear factor κ B related proteins in human amnion. Mol. Hum. Reprod.9(4), 213–218 (2003).
   PubMed Web of Science ®Google Scholar
• Lappas M, Rice GE. Transcriptional regulation of the processes of human labour and delivery. Placenta30(Suppl. A), S90–S95 (2009).
   Google Scholar
• Vora S, Abbas A, Kim CJ et al. Nuclear factor-κ B localization and function within intrauterine tissues from term and preterm labor and cultured fetal membranes. Reprod. Biol. Endocrinol.8, 8 (2010).
   PubMedGoogle Scholar
• Condon JC, Hardy DB, Kovaric K, Mendelson CR. Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-κB may contribute to the onset of labor through inhibition of PR function. Mol. Endocrinol.20(4), 764–775 (2006).
   PubMedGoogle Scholar
• Yan X, Sun M, Gibb W. Localization of nuclear factor-κB (NF κB) and inhibitory factor-κ B (IκB) in human fetal membranes and decidua at term and preterm delivery. Placenta23(4), 288–293 (2002).
   PubMedGoogle Scholar
• Brown AG, Leite RS, Strauss JF 3rd. Mechanisms underlying “functional” progesterone withdrawal at parturition. Ann. NY Acad. Sci.1034, 36–49 (2004).
   PubMed Web of Science ®Google Scholar
• Pieber D, Allport VC, Hills F, Johnson M, Bennett PR. Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol. Hum. Reprod.7(9), 875–879 (2001).
   PubMed Web of Science ®Google Scholar
• Mitchell BF, Wong S. Changes in 17 β,20 α-hydroxysteroid dehydrogenase activity supporting an increase in the estrogen/progesterone ratio of human fetal membranes at parturition. Am. J. Obstet. Gynecol.168(5), 1377–1385 (1993).
   PubMed Web of Science ®Google Scholar
• Roth I, Corry DB, Locksley RM, Abrams JS, Litton MJ, Fisher SJ. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J. Exp. Med.184(2), 539–548 (1996).
   PubMed Web of Science ®Google Scholar
• Hanna N, Hanna I, Hleb M et al. Gestational age-dependent expression of IL-10 and its receptor in human placental tissues and isolated cytotrophoblasts. J. Immunol.164(11), 5721–5728 (2000).
   PubMed Web of Science ®Google Scholar
• Lidstrom C, Matthiesen L, Berg G, Sharma S, Ernerudh J, Ekerfelt C. Cytokine secretion patterns of NK cells and macrophages in early human pregnancy decidua and blood: implications for suppressor macrophages in decidua. Am. J. Reprod. Immunol.50(6), 444–452 (2003).
   PubMed Web of Science ®Google Scholar
• Gotsch F, Romero R, Kusanovic JP et al. The anti-inflammatory limb of the immune response in preterm labor, intra-amniotic infection/inflammation, and spontaneous parturition at term: a role for interleukin-10. J. Matern. Fetal Neonatal Med.21(8), 529–547 (2008).
   PubMed Web of Science ®Google Scholar
• Maldonado-Perez D, Golightly E, Denison FC, Jabbour HN, Norman JE. A role for lipoxin A4 as anti-inflammatory and proresolution mediator in human parturition. FASEB J.25(2), 569–575 (2010).
   PubMedGoogle Scholar
• Orsi NM, Tribe RM. Cytokine networks and the regulation of uterine function in pregnancy and parturition. J. Neuroendocrinol.20(4), 462–469 (2008).
   PubMed Web of Science ®Google Scholar
• Langhoff-Roos J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I. Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study. BMJ332(7547), 937–939 (2006).
   PubMed Web of Science ®Google Scholar
• Norman JE, Morris C, Chalmers J. The effect of changing patterns of obstetric care in Scotland (1980–2004) on rates of preterm birth and its neonatal consequences: perinatal database study. PLoS Med.6(9), e1000153 (2009).
   PubMed Web of Science ®Google Scholar
• Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet371(9608), 261–269 (2008).
   PubMed Web of Science ®Google Scholar
• Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. The cost of preterm birth throughout childhood in England and Wales. Pediatrics123(2), e312–327 (2009).
   PubMed Web of Science ®Google Scholar
• Romero R, Espinoza J, Kusanovic JP et al. The preterm parturition syndrome. BJOG113(Suppl. 3), 17–42 (2006).
   PubMed Web of Science ®Google Scholar
• Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N. Engl. J. Med.342(20), 1500–1507 (2000).
   PubMed Web of Science ®Google Scholar
• Thomakos N, Daskalakis G, Papapanagiotou A, Papantoniou N, Mesogitis S, Antsaklis A. Amniotic fluid interleukin-6 and tumor necrosis factor-α at mid-trimester genetic amniocentesis: relationship to intra-amniotic microbial invasion and preterm delivery. Eur. J. Obstet. Gynecol. Reprod. Biol.148(2), 147–151 (2010).
   PubMed Web of Science ®Google Scholar
• Yoon BH, Oh SY, Romero R et al. An elevated amniotic fluid matrix metalloproteinase-8 level at the time of mid-trimester genetic amniocentesis is a risk factor for spontaneous preterm delivery. Am. J. Obstet. Gynecol.185(5), 1162–1167 (2001).
   PubMed Web of Science ®Google Scholar
• Pirianov G, Waddington SN, Lindstrom TM, Terzidou V, Mehmet H, Bennett PR. The cyclopentenone 15-deoxy-δ 12,14-prostaglandin J(2) delays lipopolysaccharide-induced preterm delivery and reduces mortality in the newborn mouse. Endocrinology150(2), 699–706 (2009).
   PubMed Web of Science ®Google Scholar
• Robertson SA, Skinner RJ, Care AS. Essential role for IL-10 in resistance to lipopolysaccharide-induced preterm labor in mice. J. Immunol.177(7), 4888–4896 (2006).
   PubMed Web of Science ®Google Scholar
• Mcduffie RS Jr, Sherman MP, Gibbs RS. Amniotic fluid tumor necrosis factor-α and interleukin-1 in a rabbit model of bacterially induced preterm pregnancy loss. Am. J. Obstet. Gynecol.167(6), 1583–1588 (1992).
   PubMed Web of Science ®Google Scholar
• Gravett MG, Witkin SS, Haluska GJ, Edwards JL, Cook MJ, Novy MJ. An experimental model for intraamniotic infection and preterm labor in rhesus monkeys. Am. J. Obstet. Gynecol.171(6), 1660–1667 (1994).
   PubMed Web of Science ®Google Scholar
• Romero R, Tartakovsky B. The natural interleukin-1 receptor antagonist prevents interleukin-1-induced preterm delivery in mice. Am. J. Obstet. Gynecol.167(4 Pt 1), 1041–1045 (1992).
   PubMed Web of Science ®Google Scholar
• Sadowsky DW, Adams KM, Gravett MG, Witkin SS, Novy MJ. Preterm labor is induced by intraamniotic infusions of interleukin-1β and tumor necrosis factor-α but not by interleukin-6 or interleukin-8 in a nonhuman primate model. Am. J. Obstet. Gynecol.195(6), 1578–1589 (2006).
   PubMed Web of Science ®Google Scholar
• Shatrov JG, Birch SC, Lam LT, Quinlivan JA, Mcintyre S, Mendz GL. Chorioamnionitis and cerebral palsy: a meta-analysis. Obstet. Gynecol.116(2 Pt 1), 387–392 (2010).
   PubMed Web of Science ®Google Scholar
• Yoon BH, Romero R, Park JS et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am. J. Obstet. Gynecol.182(3), 675–681 (2000).
   PubMed Web of Science ®Google Scholar
• Youssef RE, Ledingham MA, Bollapragada SS et al. The role of Toll-like receptors (TLR-2 and -4) and triggering receptor expressed on myeloid cells 1 (TREM-1) in human term and preterm labor. Reprod. Sci.16(9), 843–856 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YM, Romero R, Chaiworapongsa T et al. Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am. J. Obstet. Gynecol.191(4), 1346–1355 (2004).
   PubMed Web of Science ®Google Scholar
• Canavan TP, Simhan HN. Innate immune function of the human decidual cell at the maternal–fetal interface. J. Reprod. Immunol.74(1–2), 46–52 (2007).
   PubMed Web of Science ®Google Scholar
• Holmlund U, Cebers G, Dahlfors AR et al. Expression and regulation of the pattern recognition receptors Toll-like receptor-2 and Toll-like receptor-4 in the human placenta. Immunology107(1), 145–151 (2002).
   PubMed Web of Science ®Google Scholar
• Hassan SS, Romero R, Haddad R et al. The transcriptome of the uterine cervix before and after spontaneous term parturition. Am. J. Obstet. Gynecol.195(3), 778–786 (2006).
   PubMed Web of Science ®Google Scholar
• Wang H, Hirsch E. Bacterially-induced preterm labor and regulation of prostaglandin-metabolizing enzyme expression in mice: the role of Toll-like receptor 4. Biol. Reprod.69(6), 1957–1963 (2003).
   PubMed Web of Science ®Google Scholar
• Elovitz MA, Wang Z, Chien EK, Rychlik DF, Phillippe M. A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4. Am. J. Pathol.163(5), 2103–2111 (2003).
   PubMed Web of Science ®Google Scholar
• Patni S, Flynn P, Wynen LP et al. An introduction to Toll-like receptors and their possible role in the initiation of labour. BJOG114(11), 1326–1334 (2007).
   PubMed Web of Science ®Google Scholar
• Smith V, Devane D, Begley CM, Clarke M, Higgins S. A systematic review and quality assessment of systematic reviews of randomised trials of interventions for preventing and treating preterm birth. Eur. J. Obstet. Gynecol. Reprod. Biol.142(1), 3–11 (2009).
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr. Rev.65(12 Pt 2), S140–146 (2007).
   PubMed Web of Science ®Google Scholar
• Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr. Rev.65(12 Pt 2), S194–S202 (2007).
   PubMed Web of Science ®Google Scholar
• Zuckerman H, Reiss U, Rubinstein I. Inhibition of human premature labor by indomethacin. Obstet. Gynecol.44(6), 787–792 (1974).
   PubMed Web of Science ®Google Scholar
• Niebyl JR, Blake DA, White RD et al. The inhibition of premature labor with indomethacin. Am. J. Obstet. Gynecol.136(8), 1014–1019 (1980).
   PubMed Web of Science ®Google Scholar
• Panter KR, Hannah ME, Amankwah KS, Ohlsson A, Jefferies AL, Farine D. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. Br. J. Obstet. Gynaecol.106(5), 467–473 (1999).
   PubMedGoogle Scholar
• Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N. Engl. J. Med.329(22), 1602–1607 (1993).
   PubMed Web of Science ®Google Scholar
• Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann. Pharmacother.40(5), 824–829 (2006).
   PubMed Web of Science ®Google Scholar
• Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet. Gynecol.106(1), 173–179 (2005).
   PubMed Web of Science ®Google Scholar
• Kumazaki K, Nakayama M, Yanagihara I, Suehara N, Wada Y. Immunohistochemical distribution of Toll-like receptor 4 in term and preterm human placentas from normal and complicated pregnancy including chorioamnionitis. Hum. Pathol.35(1), 47–54 (2004).
   PubMed Web of Science ®Google Scholar
• Lorenz E, Hallman M, Marttila R, Haataja R, Schwartz DA. Association between the Asp299Gly polymorphisms in the Toll-like receptor 4 and premature births in the Finnish population. Pediatr. Res.52(3), 373–376 (2002).
   PubMed Web of Science ®Google Scholar
• Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol.5(10), 975–979 (2004).
   PubMed Web of Science ®Google Scholar
• Adams Waldorf KM, Persing D, Novy MJ, Sadowsky DW, Gravett MG. Pretreatment with Toll-like receptor 4 antagonist inhibits lipopolysaccharide-induced preterm uterine contractility, cytokines, and prostaglandins in rhesus monkeys. Reprod. Sci.15(2), 121–127 (2008).
   PubMed Web of Science ®Google Scholar
• Li L, Kang J, Lei W. Role of Toll-like receptor 4 in inflammation-induced preterm delivery. Mol. Hum. Reprod.16(4), 267–272 (2010).
   PubMed Web of Science ®Google Scholar
• Koga K, Cardenas I, Aldo P et al. Activation of TLR3 in the trophoblast is associated with preterm delivery. Am. J. Reprod. Immunol.61(3), 196–212 (2009).
   PubMed Web of Science ®Google Scholar
• Ilievski V, Hirsch E. Synergy between viral and bacterial Toll-like receptors leads to amplification of inflammatory responses and preterm labor in the mouse. Biol. Reprod.83(5), 767–773 (2010).
   PubMed Web of Science ®Google Scholar
• Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochem. Biophys. Acta1799(10–12), 775–787 (2010).
   PubMed Web of Science ®Google Scholar
• Okamoto T. NF-κB and rheumatic diseases. Endocr. Metab. Immune Disord. Drug Targets6(4), 359–372 (2006).
   PubMedGoogle Scholar
• Decramer M, Rutten-Van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet365(9470), 1552–1560 (2005).
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med.353(21), 2229–2242 (2005).
   PubMed Web of Science ®Google Scholar
• Atreya I, Atreya R, Neurath MF. NF-κB in inflammatory bowel disease. J. Intern. Med.263(6), 591–596 (2008).
   PubMed Web of Science ®Google Scholar
• Egan LJ, Sandborn WJ. Inhibition of nuclear factor κB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology115(5), 1295–1296 (1998).
   PubMedGoogle Scholar
• Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br. J. Rheumatol.36(3), 382–386 (1997).
   PubMedGoogle Scholar
• Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor κ B. J. Clin. Invest.101(5), 1163–1174 (1998).
   PubMed Web of Science ®Google Scholar
• Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology119(5), 1209–1218 (2000).
   PubMed Web of Science ®Google Scholar
• Lappas M, Permezel M, Georgiou HM, Rice GE. Nuclear factor κ B regulation of proinflammatory cytokines in human gestational tissues in vitro. Biol. Reprod.67(2), 668–673 (2002).
   PubMed Web of Science ®Google Scholar
• Keelan JA, Khan S, Yosaatmadja F, Mitchell MD. Prevention of inflammatory activation of human gestational membranes in an ex vivo model using a pharmacological NF-κB inhibitor. J. Immunol.183(8), 5270–5278 (2009).
   PubMed Web of Science ®Google Scholar
• Peltier MR, Tee SC, Kinzler WL, Smulian JC. Effect of sulfasalazine on basal and bacteria-stimulated interleukin-8 production by endocervical epithelial cells. Am. J. Reprod. Immunol.61(3), 190–195 (2009).
   PubMed Web of Science ®Google Scholar
• Nath CA, Ananth CV, Smulian JC, Peltier MR. Can sulfasalazine prevent infection-mediated pre-term birth in a murine model? Am. J. Reprod. Immunol.63(2), 144–149 (2010).
   PubMed Web of Science ®Google Scholar
• Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat. Rev. Rheumatol.5(7), 382–390 (2009).
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod. Toxicol.25(2), 271–275 (2008).
   PubMed Web of Science ®Google Scholar
• Millea PJ. N-acetylcysteine: multiple clinical applications. Am. Fam. Physician80(3), 265–269 (2009).
   PubMed Web of Science ®Google Scholar
• Origuchi T, Migita K, Nakashima T et al. Regulation of cyclooxygenase-2 expression in human osteoblastic cells by N-acetylcysteine. J. Lab. Clin. Med.136(5), 390–394 (2000).
   PubMed Web of Science ®Google Scholar
• Martinez-Losa M, Cortijo J, Juan G et al. Inhibitory effects of N-acetylcysteine on the functional responses of human eosinophils in vitro. Clin. Exp. Allergy.37(5), 714–722 (2007).
   PubMed Web of Science ®Google Scholar
• De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur. Respir. J.10(7), 1535–1541 (1997).
   PubMed Web of Science ®Google Scholar
• Riggs BS, Bronstein AC, Kulig K, Archer PG, Rumack BH. Acute acetaminophen overdose during pregnancy. Obstet. Gynecol.74(2), 247–253 (1989).
   PubMed Web of Science ®Google Scholar
• Rizk AY, Bedaiwy MA, Al-Inany HG. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil. Steril.83(2), 367–370 (2005).
   PubMed Web of Science ®Google Scholar
• Amin AF, Shaaban OM, Bediawy MA. N-acetyl cysteine for treatment of recurrent unexplained pregnancy loss. Reprod. Biomed. Online17(5), 722–726 (2008).
   PubMed Web of Science ®Google Scholar
• Rumiris D, Purwosunu Y, Wibowo N, Farina A, Sekizawa A. Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status. Hypertens. Pregnancy25(3), 241–253 (2006).
   PubMed Web of Science ®Google Scholar
• Buhimschi IA, Buhimschi CS, Weiner CP. Protective effect of N-acetylcysteine against fetal death and preterm labor induced by maternal inflammation. Am. J. Obstet. Gynecol.188(1), 203–208 (2003).
   PubMed Web of Science ®Google Scholar
• Beloosesky R, Gayle DA, Ross MG. Maternal N-acetylcysteine suppresses fetal inflammatory cytokine responses to maternal lipopolysaccharide. Am. J. Obstet. Gynecol.195(4), 1053–1057 (2006).
   PubMed Web of Science ®Google Scholar
• Chang EY, Zhang J, Sullivan S, Newman R, Singh I. N-acetylcysteine attenuates the maternal and fetal proinflammatory response to intrauterine LPS injection in an animal model for preterm birth and brain injury. J. Matern. Fetal. Neonatal. Med.24(5), 732–740 (2011).
   PubMed Web of Science ®Google Scholar
• Shahin AY, Hassanin IM, Ismail AM, Kruessel JS, Hirchenhain J. Effect of oral N-acetyl cysteine on recurrent preterm labor following treatment for bacterial vaginosis. Int. J. Gynaecol. Obstet.104(1), 44–48 (2009).
   PubMed Web of Science ®Google Scholar
• Kondo Y, Fukuda K, Adachi T, Nishida T. Inhibition by a selective IκB kinase-2 inhibitor of interleukin-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture. Invest. Ophthalmol. Vis. Sci.49(11), 4850–4857 (2008).
   PubMedGoogle Scholar
• Podolin PL, Callahan JF, Bolognese BJ et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Ther.312(1), 373–381 (2005).
   PubMed Web of Science ®Google Scholar
• De Silva D, Mitchell MD, Keelan JA. Inhibition of choriodecidual cytokine production and inflammatory gene expression by selective I-κB kinase (IKK) inhibitors. Br. J. Pharmacol.160(7), 1808–1822 (2010).
   PubMed Web of Science ®Google Scholar
• Osting VC, Carter JD. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin. Drug Saf.9(3), 421–429 (2010).
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm. Bowel. Dis. DOI: 10.1002/ibd.21583 (2011) (Epub ahead of print).
   Google Scholar
• Silver RM, Lohner WS, Daynes RA, Mitchell MD, Branch DW. Lipopolysaccharide-induced fetal death: the role of tumor-necrosis factor α. Biol. Reprod.50(5), 1108–1112 (1994).
   PubMed Web of Science ®Google Scholar
• Gendron RL, Nestel FP, Lapp WS, Baines MG. Lipopolysaccharide-induced fetal resorption in mice is associated with the intrauterine production of tumour necrosis factor-α. J. Reprod. Fertil.90(2), 395–402 (1990).
   PubMedGoogle Scholar
• Xu DX, Chen YH, Wang H, Zhao L, Wang JP, Wei W. Tumor necrosis factor α partially contributes to lipopolysaccharide-induced intra-uterine fetal growth restriction and skeletal development retardation in mice. Toxicol. Lett.163(1), 20–29 (2006).
   PubMed Web of Science ®Google Scholar
• Fidel PL Jr, Romero R, Cutright J et al. Treatment with the interleukin-I receptor antagonist and soluble tumor necrosis factor receptor Fc fusion protein does not prevent endotoxin-induced preterm parturition in mice. J. Soc. Gynecol. Investig.4(1), 22–26 (1997).
   PubMedGoogle Scholar
• Holmgren C, Esplin MS, Hamblin S, Molenda M, Simonsen S, Silver R. Evaluation of the use of anti-TNF-α in an LPS-induced murine model. J. Reprod. Immunol.78(2), 134–139 (2008).
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, De Haar C, De Ridder L et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment. Pharmacol. Ther.33(9), 1053–1058 (2011).
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J. Intern. Med.269(1), 16–28 (2011).
   PubMed Web of Science ®Google Scholar
• Romero R, Sepulveda W, Mazor M et al. The natural interleukin-1 receptor antagonist in term and preterm parturition. Am. J. Obstet. Gynecol.167(4 Pt 1), 863–872 (1992).
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Hirsch E. Effect of stimulation and antagonism of interleukin-1 signaling on preterm delivery in mice. J. Soc. Gynecol. Investig.12(7), 533–538 (2005).
   PubMedGoogle Scholar
• Reznikov LL, Fantuzzi G, Selzman CH et al. Utilization of endoscopic inoculation in a mouse model of intrauterine infection-induced preterm birth: role of interleukin 1β. Biol. Reprod.60(5), 1231–1238 (1999).
   PubMedGoogle Scholar
• Hirsch E, Muhle RA, Mussalli GM, Blanchard R. Bacterially induced preterm labor in the mouse does not require maternal interleukin-1 signaling. Am. J. Obstet. Gynecol.186(3), 523–530 (2002).
   PubMed Web of Science ®Google Scholar
• Hirsch E, Filipovich Y, Mahendroo M. Signaling via the type I IL-1 and TNF receptors is necessary for bacterially induced preterm labor in a murine model. Am. J. Obstet. Gynecol.194(5), 1334–1340 (2006).
   PubMed Web of Science ®Google Scholar
• Catalano RD, Lannagan TR, Gorowiec M, Denison FC, Norman JE, Jabbour HN. Prokineticins: novel mediators of inflammatory and contractile pathways at parturition? Mol. Hum. Reprod.16(5), 311–319 (2010).
   PubMedGoogle Scholar
• Denison FC, Battersby S, King AE, Szuber M, Jabbour HN. Prokineticin-1: a novel mediator of the inflammatory response in third-trimester human placenta. Endocrinology149(7), 3470–3477 (2008).
   PubMedGoogle Scholar
• Gorowiec MR, Catalano RD, Norman JE, Denison FC, Jabbour HN. Prokineticin 1 (PROK1) induces inflammatory response in human myometrium: a potential role in initiating term and preterm parturition. Am. J. Pathol. (2011) (In Press).
   PubMedGoogle Scholar
• Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug. Discov.3(5), 401–416 (2004).
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol.8(5), 349–361 (2008).
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med.170(6), 2081–2095 (1989).
   PubMed Web of Science ®Google Scholar
• Sabat R, Grutz G, Warszawska K et al. Biology of interleukin-10. Cytokine Growth Factor Rev.21(5), 331–344 (2010).
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol.147(11), 3815–3822 (1991).
   PubMed Web of Science ®Google Scholar
• De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, De Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med.174(5), 1209–1220 (1991).
   PubMed Web of Science ®Google Scholar
• Buchwald UK, Geerdes-Fenge HF, Vockler J, Ziege S, Lode H. Interleukin-10: effects on phagocytosis and adhesion molecule expression of granulocytes and monocytes in a comparison with prednisolone. Eur. J. Med. Res.4(3), 85–94 (1999).
   PubMedGoogle Scholar
• Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J. Immunol.157(8), 3672–3680 (1996).
   PubMed Web of Science ®Google Scholar
• Jenkins JK, Malyak M, Arend WP. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 β production in human monocytes and neutrophils. Lymphokine Cytokine Res.13(1), 47–54 (1994).
   PubMedGoogle Scholar
• Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor κ B (NF κ B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem.270(16), 9558–9563 (1995).
   PubMed Web of Science ®Google Scholar
• Yoshidome H, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 inhibits pulmonary NF-κB activation and lung injury induced by hepatic ischemia–reperfusion. Am. J. Physiol.277(5 Pt 1), L919–L923 (1999).
   Google Scholar
• Al-Ashy R, Chakroun I, El-Sabban ME, Homaidan FR. The role of NF-κB in mediating the anti-inflammatory effects of IL-10 in intestinal epithelial cells. Cytokine36(1–2), 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Buruiana FE, Sola I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.11, CD005109 (2010).
   Google Scholar
• Kimball AB, Kawamura T, Tejura K et al. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch. Dermatol.138(10), 1341–1346 (2002).
   PubMed Web of Science ®Google Scholar
• Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology118(4), 655–660 (2000).
   PubMed Web of Science ®Google Scholar
• Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy – review of a new approach. Pharmacol. Rev.55(2), 241–269 (2003).
   PubMed Web of Science ®Google Scholar
• Thaxton JE, Sharma S. Interleukin-10: a multi-faceted agent of pregnancy. Am. J. Reprod. Immunol.63(6), 482–491 (2010).
   PubMed Web of Science ®Google Scholar
• Kalkunte S, Nevers T, Norris WE, Sharma S. Vascular IL-10: a protective role in preeclampsia. J. Reprod. Immunol.88(2), 165–169 (2011).
   PubMed Web of Science ®Google Scholar
• Greig PC, Herbert WN, Robinette BL, Teot LA. Amniotic fluid interleukin-10 concentrations increase through pregnancy and are elevated in patients with preterm labor associated with intrauterine infection. Am. J. Obstet. Gynecol.173(4), 1223–1227 (1995).
   PubMed Web of Science ®Google Scholar
• Dudley DJ, Hunter C, Mitchell MD, Varner MW. Amniotic fluid interleukin-10 (IL-10) concentrations during pregnancy and with labor. J. Reprod. Immunol.33(2), 147–156 (1997).
   PubMed Web of Science ®Google Scholar
• Hennessy A, Pilmore HL, Simmons LA, Painter DM. A deficiency of placental IL-10 in preeclampsia. J. Immunol.163(6), 3491–3495 (1999).
   PubMed Web of Science ®Google Scholar
• Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA273(24), 1933–1936 (1995).
   PubMed Web of Science ®Google Scholar
• Makhseed M, Raghupathy R, El-Shazly S, Azizieh F, Al-Harmi JA, Al-Azemi MM. Pro-inflammatory maternal cytokine profile in preterm delivery. Am. J. Reprod. Immunol.49(5), 308–318 (2003).
   PubMed Web of Science ®Google Scholar
• Fortunato SJ, Menon R, Lombardi SJ. Interleukin-10 and transforming growth factor-β inhibit amniochorion tumor necrosis factor-α production by contrasting mechanisms of action: therapeutic implications in prematurity. Am. J. Obstet. Gynecol.177(4), 803–809 (1997).
   PubMed Web of Science ®Google Scholar
• Brown NL, Alvi SA, Elder MG, Bennett PR, Sullivan MH. The regulation of prostaglandin output from term intact fetal membranes by anti-inflammatory cytokines. Immunology99(1), 124–133 (2000).
   PubMed Web of Science ®Google Scholar
• Fortunato SJ, Menon R, Lombardi SJ, Lafleur B. Interleukin-10 inhibition of gelatinases in fetal membranes: therapeutic implications in preterm premature rupture of membranes. Obstet. Gynecol.98(2), 284–288 (2001).
   PubMed Web of Science ®Google Scholar
• Sato TA, Keelan JA, Mitchell MD. Critical paracrine interactions between TNF-α and IL-10 regulate lipopolysaccharide-stimulated human choriodecidual cytokine and prostaglandin E2 production. J. Immunol.170(1), 158–166 (2003).
   PubMed Web of Science ®Google Scholar
• Pomini F, Caruso A, Challis JR. Interleukin-10 modifies the effects of interleukin-1β and tumor necrosis factor-α on the activity and expression of prostaglandin H synthase-2 and the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase in cultured term human villous trophoblast and chorion trophoblast cells. J. Clin. Endocrinol. Metab.84(12), 4645–4651 (1999).
   PubMed Web of Science ®Google Scholar
• Roth I, Fisher SJ. IL-10 is an autocrine inhibitor of human placental cytotrophoblast MMP-9 production and invasion. Dev. Biol.205(1), 194–204 (1999).
   PubMed Web of Science ®Google Scholar
• Bayraktar M, Peltier M, Vetrano A et al. IL-10 modulates placental responses to TLR ligands. Am. J. Reprod. Immunol.62(6), 390–399 (2009).
   PubMed Web of Science ®Google Scholar
• Terrone DA, Rinehart BK, Granger JP, Barrilleaux PS, Martin JN Jr, Bennett WA. Interleukin-10 administration and bacterial endotoxin-induced preterm birth in a rat model. Obstet. Gynecol.98(3), 476–480 (2001).
   PubMed Web of Science ®Google Scholar
• Rodts-Palenik S, Wyatt-Ashmead J, Pang Y et al. Maternal infection-induced white matter injury is reduced by treatment with interleukin-10. Am. J. Obstet. Gynecol.191(4), 1387–1392 (2004).
   PubMed Web of Science ®Google Scholar
• Pang Y, Rodts-Palenik S, Cai Z, Bennett WA, Rhodes PG. Suppression of glial activation is involved in the protection of IL-10 on maternal E. coli induced neonatal white matter injury. Brain Res. Dev. Brain Res.157(2), 141–149 (2005).
   PubMedGoogle Scholar
• Sadowsky DW, Novy MJ, Witkin SS, Gravett MG. Dexamethasone or interleukin-10 blocks interleukin-1β-induced uterine contractions in pregnant rhesus monkeys. Am. J. Obstet. Gynecol.188(1), 252–263 (2003).
   PubMed Web of Science ®Google Scholar
• Gomez-Lopez N, Guilbert LJ, Olson DM. Invasion of the leukocytes into the fetal–maternal interface during pregnancy. J. Leukoc. Biol.88(4), 625–633 (2010).
   PubMed Web of Science ®Google Scholar
• Fuchs F, Stakemann G. Treatment of threatened premature labor with large doses of progesterone. Am. J. Obstet. Gynecol.79, 172–176 (1960).
   PubMed Web of Science ®Google Scholar
• Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am. J. Obstet. Gynecol.188(2), 419–424 (2003).
   PubMed Web of Science ®Google Scholar
• Meis PJ, Klebanoff M, Thom E et al. Prevention of recurrent preterm delivery by 17 α-hydroxyprogesterone caproate. N. Engl. J. Med.348(24), 2379–2385 (2003).
   PubMed Web of Science ®Google Scholar
• Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the prevention of preterm birth: a systematic review. Obstet. Gynecol.112(1), 127–134 (2008).
   PubMed Web of Science ®Google Scholar
• Norman JE, Mackenzie F, Owen P et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet373(9680), 2034–2040 (2009).
   PubMed Web of Science ®Google Scholar
• Briery CM, Veillon EW, Klauser CK et al. Progesterone does not prevent preterm births in women with twins. South Med. J.102(9), 900–904 (2009).
   PubMed Web of Science ®Google Scholar
• Combs CA, Garite T, Maurel K, Das A, Porto M. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am. J. Obstet. Gynecol.203(3), 248 e1–e9 (2010).
   PubMed Web of Science ®Google Scholar
• Briery CM, Veillon EW, Klauser CK et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am. J. Obstet. Gynecol.204(1), 54 e1–e5 (2011).
   PubMed Web of Science ®Google Scholar
• Elovitz M, Wang Z. Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise. Am. J. Obstet. Gynecol.190(3), 693–701 (2004).
   PubMed Web of Science ®Google Scholar
• Elovitz MA, Mrinalini C. Can medroxyprogesterone acetate alter Toll-like receptor expression in a mouse model of intrauterine inflammation? Am. J. Obstet. Gynecol.193(3 Pt 2), 1149–1155 (2005).
   PubMed Web of Science ®Google Scholar
• Kalkhoven E, Wissink S, Van Der Saag PT, Van Der Burg B. Negative interaction between the RelA(p65) subunit of NF-κB and the progesterone receptor. J. Biol. Chem.271(11), 6217–6224 (1996).
   PubMed Web of Science ®Google Scholar
• Luo G, Abrahams VM, Tadesse S et al. Progesterone inhibits basal and TNF-α-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth. Reprod. Sci.17(6), 532–539 (2010).
   PubMed Web of Science ®Google Scholar
• Shields AD, Wright J, Paonessa DJ et al. Progesterone modulation of inflammatory cytokine production in a fetoplacental artery explant model. Am. J. Obstet. Gynecol.193(3 Pt 2), 1144–1148 (2005).
   PubMed Web of Science ®Google Scholar
• Gotkin JL, Celver J, Mcnutt P et al. Progesterone reduces lipopolysaccharide induced interleukin-6 secretion in fetoplacental chorionic arteries, fractionated cord blood, and maternal mononuclear cells. Am. J. Obstet. Gynecol.195(4), 1015–1019 (2006).
   PubMed Web of Science ®Google Scholar
• Schwartz N, Xue X, Elovitz MA, Dowling O, Metz CN. Progesterone suppresses the fetal inflammatory response ex vivo. Am. J. Obstet. Gynecol.201(2), 211 e211–219 (2009).
   PubMed Web of Science ®Google Scholar
• Norman JE, Yuan M, Anderson L et al. Effect of prolonged in vivo administration of progesterone expression, peripheral blood leukocyte activation and circulating steroid hormone levels. Reprod. Sci.18(5), 435–446 (2011).
   PubMed Web of Science ®Google Scholar
• Dodd JM, Crowther CA. The role of progesterone in prevention of preterm birth. Int. J. Womens Health1, 73–84 (2010).
   PubMedGoogle Scholar
• Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin. Immunol.114(2), 100–109 (2005).
   PubMed Web of Science ®Google Scholar
• Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med.5(6), 698–701 (1999).
   PubMed Web of Science ®Google Scholar
• Ward C, Dransfield I, Murray J, Farrow SN, Haslett C, Rossi AG. Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I κ B α degradation using a peroxisome proliferator-activated receptor-γ-independent mechanism. J. Immunol.168(12), 6232–6243 (2002).
   PubMed Web of Science ®Google Scholar
• Rajakariar R, Hilliard M, Lawrence T et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyΔ12 14 PGJ2. Proc. Natl Acad. Sci. USA104(52), 20979–20984 (2007).
   PubMed Web of Science ®Google Scholar
• Rossi A, Kapahi P, Natoli G et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature403(6765), 103–108 (2000).
   PubMed Web of Science ®Google Scholar
• Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature391(6662), 79–82 (1998).
   PubMed Web of Science ®Google Scholar
• Mitchell MD, Kraemer DL, Strickland DM. The human placenta: a major source of prostaglandin D2. Prostaglandins Leukot. Med.8(4), 383–387 (1982).
   PubMedGoogle Scholar
• Norwitz ER, Starkey PM, Lopez Bernal A. Prostaglandin D2 production by term human decidua: cellular origins defined using flow cytometry. Obstet. Gynecol.80(3 Pt 1), 440–445 (1992).
   PubMed Web of Science ®Google Scholar
• Helliwell RJ, Keelan JA, Marvin KW et al. Gestational age-dependent up-regulation of prostaglandin D synthase (PGDS) and production of PGDS-derived antiinflammatory prostaglandins in human placenta. J. Clin. Endocrinol. Metab.91(2), 597–606 (2006).
   PubMed Web of Science ®Google Scholar
• Ackerman WE 4th, Zhang XL, Rovin BH, Kniss DA. Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFκB signal disruption in human WISH and amnion cells. Biol. Reprod.73(3), 527–535 (2005).
   PubMed Web of Science ®Google Scholar
• Lappas M, Permezel M, Rice GE. 15-deoxy-Δ(12,14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues. Placenta27(11–12), 1060–1072 (2006).
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Zhao X, Andersson R, Song Z, Yang D. Potential effects of peroxisome proliferator-activated receptor activator on LPS-induced lung injury in rats. Pulm. Pharmacol. Ther.22(4), 318–325 (2009).
   PubMed Web of Science ®Google Scholar
• Kawahito Y, Kondo M, Tsubouchi Y et al. 15-deoxy-δ(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest.106(2), 189–197 (2000).
   PubMed Web of Science ®Google Scholar
• Wada K, Nakajima A, Blumberg RS. PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn’s disease. Trends. Mol. Med.7(8), 329–331 (2001).
   PubMed Web of Science ®Google Scholar
• Serhan CN, Hamberg M, Samuelsson B. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem. Biophys. Res. Commun.118(3), 943–949 (1984).
   PubMed Web of Science ®Google Scholar
• Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl Acad. Sci. USA81(17), 5335–5339 (1984).
   PubMed Web of Science ®Google Scholar
• Lee TH, Horton CE, Kyan-Aung U, Haskard D, Crea AE, Spur BW. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin. Sci. (Lond.)77(2), 195–203 (1989).
   PubMed Web of Science ®Google Scholar
• Colgan SP, Serhan CN, Parkos CA, Delp-Archer C, Madara JL. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest.92(1), 75–82 (1993).
   PubMed Web of Science ®Google Scholar
• Papayianni A, Serhan CN, Brady HR. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J. Immunol.156(6), 2264–2272 (1996).
   PubMed Web of Science ®Google Scholar
• Filep JG, Khreiss T, Jozsef L. Lipoxins and aspirin-triggered lipoxins in neutrophil adhesion and signal transduction. Prostaglandins Leukot. Essent. Fatty Acids73(3–4), 257–262 (2005).
   PubMed Web of Science ®Google Scholar
• El Kebir D, Jozsef L, Khreiss T et al. Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J. Immunol.179(1), 616–622 (2007).
   PubMed Web of Science ®Google Scholar
• Maddox JF, Serhan CN. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med.183(1), 137–146 (1996).
   PubMed Web of Science ®Google Scholar
• Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem.272(11), 6972–6978 (1997).
   PubMed Web of Science ®Google Scholar
• Simoes RL, Niconi-De-Almeida Y, Da-Fe AR, Barja-Fidalgo C, Fierro IM. A synthetic analog of 15-epi-lipoxin A4 inhibits human monocyte apoptosis: involvement of ERK-2 and PI3-kinase. Prostaglandins Lip. Mediat.91(1–2), 10–17 (2010).
   PubMed Web of Science ®Google Scholar
• Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol.164(4), 1663–1667 (2000).
   PubMed Web of Science ®Google Scholar
• Filep JG, Zouki C, Petasis NA, Hachicha M, Serhan CN. Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. Blood94(12), 4132–4142 (1999).
   PubMed Web of Science ®Google Scholar
• Ho KJ, Spite M, Owens CD et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am. J. Pathol.177(4), 2116–2123 (2010).
   PubMed Web of Science ®Google Scholar
• Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S. Lipoxin A4 inhibits IL-1 β-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol.164(5), 2660–2666 (2000).
   PubMed Web of Science ®Google Scholar
• Gewirtz AT, Collier-Hyams LS, Young AN et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol.168(10), 5260–5267 (2002).
   PubMed Web of Science ®Google Scholar
• Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fatty Acids73(3–4), 163–177 (2005).
   PubMed Web of Science ®Google Scholar
• Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol.2(7), 612–619 (2001).
   PubMed Web of Science ®Google Scholar
• Wu SH, Liao PY, Dong L, Chen ZQ. Signal pathway involved in inhibition by lipoxin A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflamm. Res.57(9), 430–437 (2008).
   PubMed Web of Science ®Google Scholar
• Li G, Wu P, Xu Y et al. The effect of Lipoxin A4 on the interaction between macrophage and osteoblast: possible role in the treatment of aseptic loosening. BMC Musculoskelet. Disord.10, 57 (2009).
   PubMed Web of Science ®Google Scholar
• Decker Y, Mcbean G, Godson C. Lipoxin A4 inhibits IL-1β-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am. J. Physiol. Cell. Physiol.296(6), C1420–C1427 (2009).
   Web of Science ®Google Scholar
• Kure I, Nishiumi S, Nishitani Y et al. Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-κB activation. J. Pharmacol. Exp. Ther.332(2), 541–548 (2009).
   PubMed Web of Science ®Google Scholar
• Sobrado M, Pereira MP, Ballesteros I et al. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARγ-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J. Neurosci.29(12), 3875–3884 (2009).
   PubMed Web of Science ®Google Scholar
• Li Y, Cai L, Wang H et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene DOI:10.1038/onc.2011.112 (2011) (Epub ahead of print).
   Google Scholar
• Levy BD, De Sanctis GT, Devchand PR et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat. Med.8(9), 1018–1023 (2002).
   PubMed Web of Science ®Google Scholar
• Ye XH, Wu Y, Guo PP et al. Lipoxin A4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res.1323, 174–183 (2010).
   PubMed Web of Science ®Google Scholar
• Conte FP, Menezes-De-Lima O Jr, Verri WA Jr, Cunha FQ, Penido C, Henriques MG. Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects. Br. J. Pharmacol.161(4), 911–924 (2010).
   PubMed Web of Science ®Google Scholar
• Brown NL, Slater DM, Alvi SA, Elder MG, Sullivan MH, Bennett PR. Expression of 5-lipoxygenase and 5-lipoxygenase-activating protein in human fetal membranes throughout pregnancy and at term. Mol. Hum. Reprod.5(7), 668–674 (1999).
   PubMed Web of Science ®Google Scholar
• Lei ZM, Rao CV. The expression of 15-lipoxygenase gene and the presence of functional enzyme in cytoplasm and nuclei of pregnancy human myometria. Endocrinology130(2), 861–870 (1992).
   PubMed Web of Science ®Google Scholar
• Smith GC, Wu WX, Nathanielsz PW. Lipoxygenase gene expression in baboon intrauterine tissues in late pregnancy and parturition. Mol. Hum. Reprod.7(6), 587–594 (2001).
   PubMed Web of Science ®Google Scholar
• Hutchinson JL, Rajagopal SP, Sales KJ, Jabbour HN. Molecular regulators of resolution of inflammation – potential therapeutic targets in the reproductive system. Reproduction142(1), 15–28 (2011).
   PubMed Web of Science ®Google Scholar
• Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from Ω-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med.192(8), 1197–1204 (2000).
   PubMed Web of Science ®Google Scholar
• Bannenberg GL, Chiang N, Ariel A et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol.174(7), 4345–4355 (2005).
   PubMed Web of Science ®Google Scholar
• Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest.121(2), 569–581 (2011).
   PubMed Web of Science ®Google Scholar
• Duffield JS, Hong S, Vaidya VS et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol.177(9), 5902–5911 (2006).
   PubMed Web of Science ®Google Scholar
• Arita M, Yoshida M, Hong S et al. Resolvin E1, an endogenous lipid mediator derived from Ω-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl Acad. Sci. USA102(21), 7671–7676 (2005).
   PubMed Web of Science ®Google Scholar
• Allen KG, Harris MA. The role of n-3 fatty acids in gestation and parturition. Exp. Biol. Med. (Maywood)226(6), 498–506 (2001).
   PubMed Web of Science ®Google Scholar
• Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ337, a2931 (2008).
   PubMed Web of Science ®Google Scholar
• Fleischhauer FJ, Yan WD, Fischell TA. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J. Am. Coll. Cardiol.21(4), 982–989 (1993).
   PubMed Web of Science ®Google Scholar
• Stenson WF, Cort D, Rodgers J et al. Dietary supplementation with fish oil in ulcerative colitis. Ann. Intern. Med.116(8), 609–614 (1992).
   PubMed Web of Science ®Google Scholar
• Macdonald A. Ω-3 fatty acids as adjunctive therapy in Crohns disease. Gastroenterol. Nurs.29(4), 295–301; quiz 302–293 (2006).
   PubMed Web of Science ®Google Scholar
• Galarraga B, Ho M, Youssef HM et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology (Oxford)47(5), 665–669 (2008).
   PubMed Web of Science ®Google Scholar
• Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J. Long-term effect of Ω-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis. Rheum.37(6), 824–829 (1994).
   PubMed Web of Science ®Google Scholar
• Olsen SF, Sorensen JD, Secher NJ et al. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet339(8800), 1003–1007 (1992).
   PubMed Web of Science ®Google Scholar
• Borod E, Atkinson R, Barclay WR, Carlson SE. Effects of third trimester consumption of eggs high in docosahexaenoic acid on docosahexaenoic acid status and pregnancy. Lipids34(Suppl.), S231 (1999).
   Google Scholar
• Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG107(3), 382–395 (2000).
   PubMed Web of Science ®Google Scholar
• Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by preeclampsia or intrauterine growth restriction. Cochrane Database Syst. Rev.3, CD003402 (2006).
   PubMedGoogle Scholar
• Horvath A, Koletzko B, Szajewska H. Effect of supplementation of women in high-risk pregnancies with long-chain polyunsaturated fatty acids on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials. Br. J. Nutr.98(2), 253–259 (2007).
   PubMed Web of Science ®Google Scholar
• Lappas M, Mitton A, Lim R, Barker G, Riley C, Permezel M. SIRT1 is a novel regulator of key pathways of human labor. Biol. Reprod.84(1), 167–178 (2011).
   PubMed Web of Science ®Google Scholar
• Lappas M, Permezel M. The anti-inflammatory and antioxidative effects of nicotinamide, a vitamin B(3) derivative, are elicited by FoxO3 in human gestational tissues: implications for preterm birth. J. Nutr. Biochem. DOI:10.1016/j.jnutbio.2010.10.009 (2011) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Vadillo-Ortega F, Perichart-Perera O, Espino S et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on preeclampsia in high risk population: randomised controlled trial. BMJ342, d2901 (2011).
   PubMed Web of Science ®Google Scholar